Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297580 | 1.00 | REN (0.56) | RENCYP3A4 | |
| SCHEMBL1863306 | 0.85 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL1863304 | 0.85 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL968225 | 0.84 | REN (0.68) | RENCYP3A4 | |
| SCHEMBL968224 | 0.84 | REN (0.68) | RENCYP3A4 | |
| SCHEMBL12992048 | 0.83 | REN (0.59) | REN | |
| SCHEMBL1860623 | 0.83 | REN (0.57) | RENCYP3A4 | |
| SCHEMBL1860626 | 0.83 | REN (0.57) | RENCYP3A4 | |
| SCHEMBL4290227 | 0.83 | REN (0.73) | REN | |
| SCHEMBL4305980 | 0.83 | REN (0.73) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | REN 1/4885CYP3A4 1612/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | REN 1/4885CYP3A4 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.